About Zelira TX

Zelira Therapeutics Ltd (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions. Zelira has launched two proprietary formulations under the HOPE® brand for Autism in multiple US-states with plans to expand into global markets in 2020.”

The Company is also undertaking:

  • Human clinical trials focused on insomnia, autism, and opioid reduction with activities in Australia and the USA.
  • The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States.
  • The company has developed two proprietary formulations (HOPE®) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products.

Welcome to ZeliraHOPE.com

Please confirm you are a resident of the United States